Context: In April 2013, the Infectious Disease Society of America (IDSA) reported that the weak antibiotic pipeline does not match bacteria's increasing ability to develop resistance. Since 2009, only 2 new antibiotics were approved in the United States. The number of new antibiotics approved for marketing per year declines continuously. The report identified seven antibiotics against the Gram-negative bacilli (GNB) currently in phase 2 or phase 3 clinical trials. However, these drugs do not address the entire spectrum of resistance of GNB. Some of these antibiotics are combination of existent treatments:

Question: How many antibiotics have been created in the last 7 years?
Answer: 2

Question: How many are in the pipelin to fight GNB?
Answer: seven

Question: What year did the Infectious Disease Society of America say that production of new antibiotics does not keep up with resistance?
Answer: 2013

Question: How many bacilli have been created in the last 7 years?
Answer: Unanswerable

Question: How many are in the pipeline to fight IDSA?
Answer: Unanswerable

Question: What year did the Infectious Diseases of America say that production of GNB does not keep up with resistance?
Answer: Unanswerable

Question: What happens to the umber of new resistance?
Answer: Unanswerable

Question: What drugs address teh entire spectrum of resistance of GNB?
Answer: Unanswerable